Of the 1,000-2,600 people who get meningococcal disease each year, one-third are teens and young adults. Ten percent to 15% of those who get sick with the disease will die, even with antibiotic treatment. As many as 20% will have permanent side effects, such as hearing loss or brain damage.
In the U.S., two meningococcal vaccines are available:
Meningococcal polysaccharide vaccine (MPSV4), sold as Menomune
Meningococcal conjugate vaccine (MCV4), sold as Menactra, MenHibrix, and Menveo.
Each of these vaccines can prevent four types of meningococcal disease, which make up about 70% of the cases in the U.S.
MCV4 is preferred for people age 55 and younger. The recommendation for teens is one dose at age 11 and one dose at age 16. The doctor or nurse injects one dose into the muscle. If MCV4 is not available, you can use MPSV4. The doctor or nurse injects one dose beneath the skin.
MPSV4 is the only meningococcal vaccine approved for use in people over 55.
Who needs a meningococcal vaccine?
The CDC recommends a meningococcal vaccine for:
All children ages 11-18 or certain younger high-risk children
Anyone who has been exposed to meningitis during an outbreak
Anyone traveling to or living where meningitis is common, such as in sub-Saharan Africa
Your preteen or teen shouldn't get the meningococcal vaccine if he or she:
Has had a severe, life-threatening allergic reaction to a meningococcal vaccine before or to any vaccine component
Is moderately or severely ill (reschedule when you are well)
Has ever had Guillain-Barre syndrome
Pregnant women can get the meningococcal vaccine, but it's only recommended for those with certain immune problems or those likely to be exposed to meningitis. With the newer MCV4 vaccines, there hasn't been as much study in pregnant women compared to the MPSV4 vaccine.